Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Compass Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CMPX
Nasdaq
2830
www.compasstherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Compass Therapeutics, Inc.
3 Penny Stocks On US Exchanges With Market Caps Under $500M
- Feb 6th, 2025 12:06 am
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
- Jan 29th, 2025 1:00 pm
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
- Jan 8th, 2025 1:00 pm
US Penny Stocks To Watch In January 2025
- Jan 7th, 2025 5:08 pm
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
- Dec 10th, 2024 1:00 pm
Top US Penny Stocks To Watch In December 2024
- Dec 4th, 2024 12:08 am
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
- Dec 2nd, 2024 1:00 pm
Compass Therapeutics to Participate in Upcoming Investor Events
- Nov 13th, 2024 1:30 pm
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
- Nov 12th, 2024 1:00 pm
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Nov 8th, 2024 3:05 pm
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M
- Nov 5th, 2024 8:04 pm
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
- Oct 4th, 2024 2:31 pm
Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)
- Aug 22nd, 2024 11:01 am
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
- Aug 12th, 2024 12:00 pm
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
- Aug 7th, 2024 12:00 pm
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
- Aug 6th, 2024 12:00 pm
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
- Jul 12th, 2024 12:05 pm
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
- May 30th, 2024 12:00 pm
Compass Therapeutics Announces CEO Transition
- May 28th, 2024 8:10 pm
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
- May 23rd, 2024 9:05 pm
Scroll